--- title: "AstraZeneca Stock And 2 UK Value Shares Trading Below Cash Flow Estimates" type: "News" locale: "en" url: "https://longbridge.com/en/news/292419901.md" description: "The article highlights three UK-listed stocks trading below cash flow estimates: AstraZeneca, Foresight Group Holdings, and BAE Systems. It analyzes their fundamentals, including revenue, market cap, and valuation metrics like DCF and P/E ratios. While these companies show strengths such as strong cash generation or order backlogs, risks include pipeline reliance, fee pressure, and supply chain bottlenecks. The piece aims to help investors identify undervalued opportunities based on disciplined valuation amidst mixed macroeconomic signals." datetime: "2026-07-13T01:08:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292419901.md) - [en](https://longbridge.com/en/news/292419901.md) - [zh-HK](https://longbridge.com/zh-HK/news/292419901.md) --- # AstraZeneca Stock And 2 UK Value Shares Trading Below Cash Flow Estimates With central banks juggling inflation and growth, energy prices feeding through to consumer bills, and bond markets reacting to every policy hint, many investors are looking for reassurance in company cash flows and valuation discipline. Undervalued stocks based on cash flows can help you focus on businesses where prices sit below SWS DCF estimates of fair value, regardless of sector. That can be useful when inflation trends, trade balances, and growth signals are mixed across regions. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener for investors who want to stick to fundamentals. ## AstraZeneca (LSE:AZN) **Overview:** AstraZeneca is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines for cancer, cardiovascular, kidney and metabolic conditions, respiratory and immune disorders, vaccines, and rare diseases, supplying primary and specialist doctors across major regions including the UK, the Americas, Europe, Asia, Africa, and Australasia. **Operations:** AstraZeneca generates about US$60.4b in revenue, almost entirely from its pharmaceuticals business. **Market Cap:** £199.1b Investors looking at AstraZeneca are getting a large pharma company with a deep late stage pipeline in oncology and rare diseases, earnings growth that has been solid, and a DCF estimate that sits well above the current share price, which points to potential mispricing on cash flows. Earnings have been growing strongly, profitability metrics such as a 21.9% ROE and 17.2% net margin are robust, and analysts see further upside if pipeline launches and AI driven efficiency gains materialize. At the same time, heavy reliance on blockbuster drugs and higher debt, plus recent trial setbacks like Wainua, highlight why pipeline risk and funding conditions still matter. The full picture of how these strengths and pressures come together is where the investment debate on AstraZeneca becomes particularly important. AstraZeneca’s strong cash generation and pipeline headlines may only be half the story, with the real tension between its current price and cash flow signals sitting inside the DCF valuation analysis for AstraZeneca AZN Discounted Cash Flow as at Jul 2026 ## Foresight Group Holdings (LSE:FSG) **Overview:** Foresight Group Holdings is a London based asset manager that invests in infrastructure, private equity and venture stage companies, giving institutional and retail investors exposure to areas such as renewable energy, social and digital infrastructure, and smaller growth businesses. **Operations:** Foresight Group Holdings generates about £114.8m of revenue from Real Assets and £50.1m from Private Equity, with most of its £165m total coming from the United Kingdom and Australia. **Market Cap:** £507.0m Investors interested in Foresight Group Holdings are looking at an asset manager whose business sits at the intersection of energy transition, infrastructure and smaller company investing, with revenue and earnings that have recently grown faster than the wider UK market and a P/E below both peer and industry averages. Strong profit margins, high current and forecast ROE, and an active buyback programme that is reducing share count all point to a management team focused on compounding value, but rising costs, fee pressure, regulatory scrutiny and dependence on performance fees mean profits can be sensitive if fundraising or investment outcomes soften. The key question is how these growth drivers and risks balance out against the current discount to estimated fair value and analyst targets. Foresight Group Holdings appears to have faster growing revenues, solid profit margins and a lower P/E, which could be masking a bigger story about how it earns those fees and scales Real Assets versus Private Equity, and the analysis report for Foresight Group Holdings hints at where that balance could quietly tilt next. LSE:FSG P/E Ratio as at Jul 2026 ## BAE Systems (LSE:BA.) **Overview:** BAE Systems is a global defense and aerospace company that supplies military aircraft, combat vehicles, submarines, weapons, munitions, electronics, and cyber security services to governments and defense customers across the US, UK, Europe, the Middle East, Australia, Saudi Arabia, and other regions. **Operations:** BAE Systems generates most of its revenue from Electronic Systems (£7.5b), Air (£7.4b), Maritime (£6.6b), and Platforms & Services (£5.0b), with smaller contributions from Cyber & Intelligence (£2.4b) and HQ activities. **Market Cap:** £52.5b BAE Systems appears on this cash flow focused list because it combines a £75b order backlog and exposure to areas such as drones, electronic warfare, satellites, and energy storage with a share price that still sits below some DCF and analyst value signals. Earnings expectations currently assume a faster pace than the wider UK market, supported by reported increases in defense budgets across NATO and Indo Pacific partners. Recent US Army and space contracts illustrate how programs can feed that pipeline. However, heavy dependence on large government contracts, elevated borrowing, ESG pushback, and supply chain bottlenecks could all affect how quickly that backlog converts into cash. How those factors align with today’s valuation is central to the investment case in BAE Systems. BAE Systems has a £75b backlog and a share price that some cash flow estimates see as lagging that pipeline, so the real question is what the analyst forecasts for BAE Systems reveal about how quickly that gap could close. LSE:BA. Earnings & Revenue Growth as at Jul 2026 The three stocks covered here are only a starting point. The full Undervalued Stocks Based On Cash Flows screener surfaces 35 more companies that pair discounted cash flow valuations with equally compelling narratives that you have not seen yet through the Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify, filter and analyze the catalysts that matter to you, from cash flow durability to balance sheet strength, so you can focus on the highest conviction ideas in minutes instead of hours. ## Take Control of Your Investment Journey If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market. ## Seeking Alternatives Before Everyone Else? Fresh ideas move first, and the stocks with real breakout potential often gain momentum while most investors are still caught looking back. Scan these under the radar picks now and consider acting early. - Identify fast-moving, smaller companies where strong balance sheets support the story by running the list of solid balance sheet and fundamentals (20 results) before the crowd catches on. - Explore potential income-focused companies with sizable yields and resilient cash coverage by screening through the 3 dividend fortresses while they are still reasonably priced. - Follow the AI buildout with companies supplying essential infrastructure by checking the curated 52 AI infrastructure stocks before momentum accelerates. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if BAE Systems might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [BAESY.US](https://longbridge.com/en/quote/BAESY.US.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [BA.UK](https://longbridge.com/en/quote/BA.UK.md) ## Related News & Research - [AstraZeneca in talks over £300bn mega-merger with US rival – reports](https://longbridge.com/en/news/294669830.md) - [Basecamp Wealth Advisors LLC Cuts Stock Holdings in Astrazeneca Plc $AZN](https://longbridge.com/en/news/294653825.md) - [Astrazeneca Plc (NYSE:AZN) Receives Average Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/294163603.md) - [Keel Point LLC Sells 7,624 Shares of Astrazeneca Plc $AZN](https://longbridge.com/en/news/294671516.md) - [Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition](https://longbridge.com/en/news/293936488.md)